Morgan S. A. Gilman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Morgan S. A. Gilman has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Andrew C. Kruse
Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
6 shared publications - Joseph J. Loparo
Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA
3 shared publications Claire Bourett
Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School
2 shared publications- Conor McMahon
Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA
2 shared publications - Elayne M. Fivenson
Department of Microbiology, Blavatnik Institute, Harvard Medical School
2 shared publications - Irina Shlosman
Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School
2 shared publications
Latest Publications
- 2 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (865)
Multifunctional antibody responses from a primate Shigella outbreak inform vaccine design
There is currently no approved vaccine for Shigella spp., a leading cause of diarrhea with increasing rates of antimicrobial resistance. Shigella vaccine development is complicated in part by an incomplete understanding of the structural and molecular determinants of immunity. To address this, we isolated monoclonal antibodies against candidate Shigella vaccine antigens using samples from a Shigella flexneri outbreak in a nonhuman primate (NHP) research facility. We found that antibodies targeting the Shigella O-antigen can undergo substantial affinity maturation (>10%) to acquire broad cross-reactivity across S. flexneri serotypes. We also found that the virulence-associated type III secretion system (T3SS) proteins IpaD and IpaB elicit moderate T cell and robust antibody responses. T3SS antibodies could either inhibit or enhance bacterial virulence in vitro and differed in vivo depending on their epitope specificity. Collectively, these findings provide insights into protective and deleterious immune responses against Shigella that directly inform vaccine immunogen design.
- 2 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (865)
Multifunctional antibody responses from a primate Shigella outbreak inform vaccine design
There is currently no approved vaccine for Shigella spp., a leading cause of diarrhea with increasing rates of antimicrobial resistance. Shigella vaccine development is complicated in part by an incomplete understanding of the structural and molecular determinants of immunity. To address this, we isolated monoclonal antibodies against candidate Shigella vaccine antigens using samples from a Shigella flexneri outbreak in a nonhuman primate (NHP) research facility. We found that antibodies targeting the Shigella O-antigen can undergo substantial affinity maturation (>10%) to acquire broad cross-reactivity across S. flexneri serotypes. We also found that the virulence-associated type III secretion system (T3SS) proteins IpaD and IpaB elicit moderate T cell and robust antibody responses. T3SS antibodies could either inhibit or enhance bacterial virulence in vitro and differed in vivo depending on their epitope specificity. Collectively, these findings provide insights into protective and deleterious immune responses against Shigella that directly inform vaccine immunogen design.
- Open Access
- 4 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (32)
Activation of the angiotensin II type I receptor by a nonpeptide agonist
The angiotensin II type I receptor (AT1R) is a G protein–coupled receptor that regulates the cardiovascular system and as a result is one of the most successful pharmacological targets for the treatment of hypertension. Within the angiotensin receptor pharmacological landscape, agonists are peptide ligands, whereas potent antagonists are predominantly small molecules. Three decades ago, a small number of nonpeptide AT1R agonists were identified. These molecules largely share a chemical scaffold with AT1R antagonists, but appeared to interact with the receptor in a manner that diverges from both antagonists and peptide agonists. Here, we revisit L-162,313, the prototype nonpeptide AT1R agonist and determine how the antagonist-like chemical scaffold acts as an agonist. L-162,313 binds similarly to AT1R antagonists, but unlike antagonists, it engages the same activation switches as peptide agonists. We map the spatial relationship required for activation of AT1R by nonpeptide agonists and used this information to design a small library of L-162,313 derivatives. These rationally designed derivatives had the expected reduced or enhanced potency based on the structural basis for activation. Our data resolve a long-standing pharmacological mystery and provide a foundation for generating more efficacious small molecule AT1R agonists.
- 4 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (32)
Open AccessActivation of the angiotensin II type I receptor by a nonpeptide agonist
The angiotensin II type I receptor (AT1R) is a G protein–coupled receptor that regulates the cardiovascular system and as a result is one of the most successful pharmacological targets for the treatment of hypertension. Within the angiotensin receptor pharmacological landscape, agonists are peptide ligands, whereas potent antagonists are predominantly small molecules. Three decades ago, a small number of nonpeptide AT1R agonists were identified. These molecules largely share a chemical scaffold with AT1R antagonists, but appeared to interact with the receptor in a manner that diverges from both antagonists and peptide agonists. Here, we revisit L-162,313, the prototype nonpeptide AT1R agonist and determine how the antagonist-like chemical scaffold acts as an agonist. L-162,313 binds similarly to AT1R antagonists, but unlike antagonists, it engages the same activation switches as peptide agonists. We map the spatial relationship required for activation of AT1R by nonpeptide agonists and used this information to design a small library of L-162,313 derivatives. These rationally designed derivatives had the expected reduced or enhanced potency based on the structural basis for activation. Our data resolve a long-standing pharmacological mystery and provide a foundation for generating more efficacious small molecule AT1R agonists.
- Open Access
- 3 November 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (45)
Conformational regulation of two essential activators of bacterial cell elongation
The peptidoglycan (PG) cell wall is critical for bacterial growth and survival and is a primary antibiotic target. MreD is an essential accessory factor of the Rod complex, which carries out PG synthesis during elongation, yet little is known about how MreD facilitates this process. Here, we present the cryoelectron microscopy structure of Thermus thermophilus MreD in complex with another essential Rod complex component, MreC. The structure reveals that a periplasmic-facing pocket of MreD interacts with multiple membrane-proximal regions of MreC. We use single-molecule FRET to show that MreD controls the conformation of MreC through these contacts, inducing a state primed for Rod complex activation. Using Escherichia coli as a model, we demonstrate that disrupting these interactions abolishes Rod complex activity in vivo. Our findings reveal the role of MreD in bacterial cell shape determination and highlight its potential as an antibiotic target.
- 3 November 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (45)
Open AccessConformational regulation of two essential activators of bacterial cell elongation
The peptidoglycan (PG) cell wall is critical for bacterial growth and survival and is a primary antibiotic target. MreD is an essential accessory factor of the Rod complex, which carries out PG synthesis during elongation, yet little is known about how MreD facilitates this process. Here, we present the cryoelectron microscopy structure of Thermus thermophilus MreD in complex with another essential Rod complex component, MreC. The structure reveals that a periplasmic-facing pocket of MreD interacts with multiple membrane-proximal regions of MreC. We use single-molecule FRET to show that MreD controls the conformation of MreC through these contacts, inducing a state primed for Rod complex activation. Using Escherichia coli as a model, we demonstrate that disrupting these interactions abolishes Rod complex activity in vivo. Our findings reveal the role of MreD in bacterial cell shape determination and highlight its potential as an antibiotic target.
- Open Access
MreC-MreD structure reveals a multifaceted interface that controls MreC conformation
The peptidoglycan (PG) cell wall is critical for bacterial growth and survival and is a primary antibiotic target. MreD is an essential accessory factor of the Rod complex, which carries out PG synthesis during elongation, yet little is known about how MreD facilitates this process. Here, we present the cryo-electron microscopy structure of Thermus thermophilus MreD in complex with another essential Rod complex component, MreC. The structure reveals that a periplasmic-facing pocket of MreD interacts with multiple membrane-proximal regions of MreC. We use single-molecule FRET to show that MreD controls the conformation of MreC through these contacts, inducing a state primed for Rod complex activation. Using E. coli as a model, we demonstrate that disrupting these interactions abolishes Rod complex activity in vivo . Our findings reveal the role of MreD in bacterial cell shape determination and highlight its potential as an antibiotic target.
Open AccessMreC-MreD structure reveals a multifaceted interface that controls MreC conformation
The peptidoglycan (PG) cell wall is critical for bacterial growth and survival and is a primary antibiotic target. MreD is an essential accessory factor of the Rod complex, which carries out PG synthesis during elongation, yet little is known about how MreD facilitates this process. Here, we present the cryo-electron microscopy structure of Thermus thermophilus MreD in complex with another essential Rod complex component, MreC. The structure reveals that a periplasmic-facing pocket of MreD interacts with multiple membrane-proximal regions of MreC. We use single-molecule FRET to show that MreD controls the conformation of MreC through these contacts, inducing a state primed for Rod complex activation. Using E. coli as a model, we demonstrate that disrupting these interactions abolishes Rod complex activity in vivo . Our findings reveal the role of MreD in bacterial cell shape determination and highlight its potential as an antibiotic target.
- Open Access
Antibodies Expand the Scope of Angiotensin Receptor Pharmacology
G protein-coupled receptors (GPCRs) are key regulators of human physiology and are the targets of many small molecule research compounds and therapeutic drugs. While most of these ligands bind to their target GPCR with high affinity, selectivity is often limited at the receptor, tissue, and cellular level. Antibodies have the potential to address these limitations but their properties as GPCR ligands remain poorly characterized. Here, using protein engineering, pharmacological assays, and structural studies, we develop maternally selective heavy chain-only antibody (“nanobody”) antagonists against the angiotensin II type I receptor (AT1R) and uncover the unusual molecular basis of their receptor antagonism. We further show that our nanobodies can simultaneously bind to AT1R with specific small-molecule antagonists and demonstrate that ligand selectivity can be readily tuned. Our work illustrates that antibody fragments can exhibit rich and evolvable pharmacology, attesting to their potential as next-generation GPCR modulators.
Open AccessAntibodies Expand the Scope of Angiotensin Receptor Pharmacology
G protein-coupled receptors (GPCRs) are key regulators of human physiology and are the targets of many small molecule research compounds and therapeutic drugs. While most of these ligands bind to their target GPCR with high affinity, selectivity is often limited at the receptor, tissue, and cellular level. Antibodies have the potential to address these limitations but their properties as GPCR ligands remain poorly characterized. Here, using protein engineering, pharmacological assays, and structural studies, we develop maternally selective heavy chain-only antibody (“nanobody”) antagonists against the angiotensin II type I receptor (AT1R) and uncover the unusual molecular basis of their receptor antagonism. We further show that our nanobodies can simultaneously bind to AT1R with specific small-molecule antagonists and demonstrate that ligand selectivity can be readily tuned. Our work illustrates that antibody fragments can exhibit rich and evolvable pharmacology, attesting to their potential as next-generation GPCR modulators.
- Open Access
Allosteric activation of cell wall synthesis during bacterial growth
Summary: The peptidoglycan (PG) cell wall protects bacteria against osmotic lysis and determines cell shape, making this structure a key antibiotic target. Peptidoglycan is a polymer of glycan chains connected by peptide crosslinks, and its synthesis requires precise spatiotemporal coordination between glycan polymerization and crosslinking. However, the molecular mechanism by which these reactions are initiated and coupled is unclear. Here we use single-molecule FRET and cryo-EM to show that an essential PG synthase (RodA-PBP2) responsible for bacterial elongation undergoes dynamic exchange between closed and open states. Structural opening couples the activation of polymerization and crosslinking and is essential in vivo. Given the high conservation of this family of synthases, the opening motion that we uncovered likely represents a conserved regulatory mechanism that controls activation of PG synthesis during other cellular processes, including cell division.
Open AccessAllosteric activation of cell wall synthesis during bacterial growth
Summary: The peptidoglycan (PG) cell wall protects bacteria against osmotic lysis and determines cell shape, making this structure a key antibiotic target. Peptidoglycan is a polymer of glycan chains connected by peptide crosslinks, and its synthesis requires precise spatiotemporal coordination between glycan polymerization and crosslinking. However, the molecular mechanism by which these reactions are initiated and coupled is unclear. Here we use single-molecule FRET and cryo-EM to show that an essential PG synthase (RodA-PBP2) responsible for bacterial elongation undergoes dynamic exchange between closed and open states. Structural opening couples the activation of polymerization and crosslinking and is essential in vivo. Given the high conservation of this family of synthases, the opening motion that we uncovered likely represents a conserved regulatory mechanism that controls activation of PG synthesis during other cellular processes, including cell division.